CClinicalTrials.gg
Status unknownNCT01531283UAGUpdated Nov 14, 2012

Deacylated Ghrelin and Beta Cell Function

An interventional study of unacylated ghrelin and acyl ghrelin in the Diabetic Process, sponsored by David Dalessio. Status unknown at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-14.

Sponsored by David Dalessio · Not applicable and Interventional

The sponsor has not verified this record recently (last verified Nov 2012), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Use of human unacylated ghrelin (UAG, also called des-octanoyl ghrelin) to study physiology in healthy subjects. The proposed research is an investigator-initiated study funded by the National Institutes of Health designed to examine the effect of physiologic levels of UAG on the regulation of glucose homeostasis as well as beta cell function.

02

Conditions studied

  • the Diabetic Process

Keywords

  • unacylated ghrelin
  • beta cell function
03

In context

Lead sponsor

David Dalessio is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Apparently healthy men and women. Only premenopausal women who are using an adequate method of contraception at Screening and who agree to continue the contraception during the study will be included. Male subjects do not need to use on birth control.
  2. Ages between 18 and 50 years, inclusive.
  3. BMI between 18.5 and 29.9 kg/m2, inclusive

Exclusion criteria

Exclusion Criteria:

  1. History or clinical evidence of impaired fasting glucose or impaired glucose tolerance or diabetes mellitus, myocardial infarction, history or symptoms of congestive heart failure, history of cancer or anorexia nervosa, history or active liver or renal disease (AST or ALT >2x upper limits of normal, calculated glomerular filtration rate [GFR] \<60).
  2. A baseline resting systolic blood pressure of less than 100 mm Hg.
  3. History of growth hormone deficiency or excess disorders (acromegaly, pituitary gigantism, panhypopituitarism); history of adrenal insufficiency or Cushing's disease/syndrome; history of neuroendocrine tumors.
  4. Anemia defined as hematocrit \<33%.
  5. Use of medications that alter insulin sensitivity: niacin, glucocorticoids, metformin, thiazolidinediones, exenatide, or atypical anti-psychotics.
  6. Pregnancy or lactation.
  7. BMI \<18 kg/m2 or BMI >30 kg/m2; fasting plasma glucose >100 mg/dl and/or 2 hr plasma glucose >140 mg/dl on a 75 g oral glucose tolerance test.
  8. Electrocardiogram (ECG) abnormalities: specifically, myocardial ischemia, previous myocardial ischemia, atrial fibrillation, second or third degree heart block and complete right or left bundle branch block.
  9. Females who are on progesterone-only contraception and those who have irregular menses.
05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    decaylated ghrelin

    UAG (4.0 µg/kg/hr)

    Drug: unacylated ghrelin

  • Experimental
    acyl ghrelin

    AG (1.0 µg/kg/hr)

    Drug: acyl ghrelin

  • Experimental
    combined acyl and desacyl ghrelin

    the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr)

    Drug: combined acyl and desacyl ghrelin

  • Placebo comparator
    saline

    saline

    Drug: saline

Interventions

  • Drugunacylated ghrelin

    IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)

  • Drugacyl ghrelin

    IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)

  • Drugcombined acyl and desacyl ghrelin

    IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)

  • Drugsaline

    IV, saline, one time, for the duration of the study visit(approximately 5 hours)

06

What researchers measure

Primary outcomes

  1. acute insulin release (AIRg)

    The primary outcome measure will be AIRg. This is calculated as the incremental insulin release,following IV glucose administration. (For the first ten minutes of the study visit.)

    Time frame: one year

Secondary outcomes

  1. Insulin sensitivity

    1. Insulin sensitivity is quantified as the insulin sensitivity index (SI) using Bergman's minimal model of glucose kinetics from the glucose and insulin results obtained from a FSIGT.

    Time frame: one year

  2. Disposition index

    2. The disposition index (DI) is a measure of β-cell function. It accounts for the modulating effect of insulin sensitivity on β-cell responses. It is calculated as the product of the SI and AIRg

    Time frame: one year

  3. glucose tolerance

    3. Glucose tolerance is measured by glucose disappearance constant. This is calculated as the slope of the natural log of glucose during the study visit, during a set time frame.

    Time frame: one year

07

Study locations

1 site
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01531283
Lead sponsor
David Dalessio
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
David Dalessio (Professor, University of Cincinnati) — Sponsor-investigator
First posted
Feb 10, 2012
Start date
Feb 2011
Primary completion
Apr 2013 (estimated)
Last update
Nov 14, 2012

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion